162 related articles for article (PubMed ID: 38207249)
1. Understanding the Termination of Urologic Cancer Clinical Trials: Insights and Challenges.
Alhajahjeh A; Hmeidan M; Elatrsh M; Al-Abbadi F; Kakish D; Sukerji R; Salah M; Al Awamlh BAH; Lee DI; Shahait M
JCO Glob Oncol; 2024 Jan; 10():e2300349. PubMed ID: 38207249
[TBL] [Abstract][Full Text] [Related]
2. Estimating the rate and reasons of clinical trial failure in urologic oncology.
Stensland KD; DePorto K; Ryan J; Kaffenberger S; Reinstatler LS; Galsky M; Canes D; Skolarus TA; Moinzadeh A
Urol Oncol; 2021 Mar; 39(3):154-160. PubMed ID: 33257221
[TBL] [Abstract][Full Text] [Related]
3. Early Termination of Oncology Clinical Trials in the United States.
Zhang E; DuBois SG
Cancer Med; 2023 Mar; 12(5):5517-5525. PubMed ID: 36305832
[TBL] [Abstract][Full Text] [Related]
4. Analysis of the Frequency, Characteristics, and Reasons for Termination of Spine-related Clinical Trials.
Caruana DL; Nam-Woo Kim D; Galivanche AR; David WB; Justen MA; Moushey AM; Sheth AH; Paranjpe MD; Grauer JN
Clin Spine Surg; 2022 Aug; 35(7):E596-E600. PubMed ID: 35351841
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, characteristics, and predictors of early termination of cardiovascular clinical trials due to low recruitment: insights from the ClinicalTrials.gov registry.
Bernardez-Pereira S; Lopes RD; Carrion MJ; Santucci EV; Soares RM; de Oliveira Abreu M; Laranjeira LN; Ikeoka DT; Zazula AD; Moreira FR; Cavalcanti AB; Mesquita ET; Peterson ED; Califf RM; Berwanger O;
Am Heart J; 2014 Aug; 168(2):213-9.e1. PubMed ID: 25066561
[TBL] [Abstract][Full Text] [Related]
6. Premature Clinical Trial Discontinuation in the Era of Immune Checkpoint Inhibitors.
Khunger M; Rakshit S; Hernandez AV; Pasupuleti V; Glass K; Galsky MD; Grivas P
Oncologist; 2018 Dec; 23(12):1494-1499. PubMed ID: 30068783
[TBL] [Abstract][Full Text] [Related]
7. Analysis of factors leading to early termination in glioblastoma-related clinical trials.
Shah HA; Mishra A; Gouzoulis MJ; Ben-Shalom N; D'Amico RS
J Neurooncol; 2022 Jul; 158(3):489-495. PubMed ID: 35648307
[TBL] [Abstract][Full Text] [Related]
8. Analysis of the frequency, characteristics, and reasons for termination of shoulder- and elbow-related clinical trials.
Caruana DL; Gouzoulis MJ; McLaughlin WM; Grauer JN
J Shoulder Elbow Surg; 2022 Sep; 31(9):1922-1928. PubMed ID: 35398166
[TBL] [Abstract][Full Text] [Related]
9. Terminated Trials in the ClinicalTrials.gov Results Database: Evaluation of Availability of Primary Outcome Data and Reasons for Termination.
Williams RJ; Tse T; DiPiazza K; Zarin DA
PLoS One; 2015; 10(5):e0127242. PubMed ID: 26011295
[TBL] [Abstract][Full Text] [Related]
10. Variation in Accrual and Race/Ethnicity Reporting in Urological and Nonurological Related Cancer Trials.
Paul K; Sathianathen N; Dahm P; Le C; Konety BR
J Urol; 2019 Aug; 202(2):385-391. PubMed ID: 31074679
[TBL] [Abstract][Full Text] [Related]
11. Assessing clinical trial failure risk factors and reasons in gastric cancer.
Zhang Z; Yin J; Yue Y; Su Y; Jiang H
BMC Gastroenterol; 2022 Nov; 22(1):496. PubMed ID: 36451088
[TBL] [Abstract][Full Text] [Related]
12. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
13. Analysis of Terminated Hand and Wrist-Related Clinical Trials.
Delma S; Foster BK; Baylor JL; Ozdag Y; Manzar S; Langford K; Klena JC; Grandizio LC
J Hand Surg Glob Online; 2023 Sep; 5(5):673-676. PubMed ID: 37790828
[TBL] [Abstract][Full Text] [Related]
14. Assessing Genitourinary Cancer Clinical Trial Accrual Sufficiency Using Archived Trial Data.
Stensland K; Kaffenberger S; Canes D; Galsky M; Skolarus T; Moinzadeh A
JCO Clin Cancer Inform; 2020 Jul; 4():614-622. PubMed ID: 32667822
[TBL] [Abstract][Full Text] [Related]
15. Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.
Mitchell AP; Hirsch BR; Abernethy AP
Trials; 2014 Mar; 15():92. PubMed ID: 24661848
[TBL] [Abstract][Full Text] [Related]
16. Reasons for and associated characteristics with early study termination: Analysis of ClinicalTrials.gov data on pregnancy topics.
Shieh C; Ofner S; Draucker CB
Nurs Outlook; 2022; 70(2):271-279. PubMed ID: 35090741
[TBL] [Abstract][Full Text] [Related]
17. Noncompletion and nonpublication of trials studying rare diseases: A cross-sectional analysis.
Rees CA; Pica N; Monuteaux MC; Bourgeois FT
PLoS Med; 2019 Nov; 16(11):e1002966. PubMed ID: 31751330
[TBL] [Abstract][Full Text] [Related]
18. Urologic de novo malignancies after kidney transplantation: a single center experience.
Karczewski M; Czapiewski W; Karczewski J
Transplant Proc; 2012 Jun; 44(5):1293-7. PubMed ID: 22664003
[TBL] [Abstract][Full Text] [Related]
19. Discontinuation and non-publication of heart failure randomized controlled trials: a call to publish all trial results.
Khan MS; Shahid I; Asad N; Greene SJ; Khan SU; Doukky R; Metra M; Anker SD; Filippatos GS; Fonarow GC; Butler J
ESC Heart Fail; 2021 Feb; 8(1):16-25. PubMed ID: 33191637
[TBL] [Abstract][Full Text] [Related]
20. The history and future of the Urologic Oncology Study Group (UOSG) of the Japan Clinical Oncology Group (JCOG).
Tobisu K
Jpn J Clin Oncol; 2012 May; 42(5):363-7. PubMed ID: 22450928
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
